VAPO News and Press, Vapotherm Inc. From 04/06/22

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced preliminary unaudited revenue for the quarter ended March 31, 2022. The Company also announced withdrawal of its full year 2022 revenue guidance (issued on January 12, 2022 and reite...

Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on developing innovative, non-invasive technologies and digital health solutions for respiratory patients, today announced a strategic partnership with Carnegie Mellon University, a world class AI research institu...

Vapotherm, Inc. (VAPO) Q4 2021 Earnings Conference Call February 24, 2022 16:30 ET Company Participants Mark Klausner - Investor Relations Joe Army - President and Chief Executive Officer John Landry - Senior Vice President and Chief Financial Officer Conference Call Participants Bill Plovani...

Vapotherm press release (NYSE:VAPO): Q4 GAAP EPS of -$0.71. Revenue of $22.2M (-45.7% Y/Y). Adjusted EBITDA was negative $13.5 million for the fourth quarter of 2021 as compared to negative $9.1 million for the fourth quarter of 2020.  For fiscal 2022, net revenue is expected to be in th...

2021 Revenue of $113.3 Million Reflects Two-Year Compounded Annual Growth Rate of 53% Results in Line with Preliminary Revenue of $112.8 Million Worldwide Installed Base of Precision Flow Hi-VNI ® Systems Now 35,200 New Debt Facility Prov...

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acu...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or ac...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages ...

Vapotherm, Inc. (VAPO) Q3 2021 Earnings Conference Call November 3, 2021 04:30 PM ET Company Participants Mark Klausner - Westwicke Investor Relations Joe Army - President and CEO John Landry - SVP and CFO Conference Call Participants Margaret Kaczor - William Blair Bill Plovanic - Canaccord ...

Vapotherm (NYSE:VAPO): Q3 GAAP EPS of -$0.52 in-line. Revenue of $38.1M (+24.5% Y/Y) beats by $7.21M. Press Release FY21 outlook: The company now expects full year revenue to be greater than $106 million, which represents an increase of $4 million over the Company’s updated guidance of...